In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
The stock's fall snapped a five-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
